2-Year Results of Paclitaxel-Eluting Balloons for Femoropopliteal Artery Disease

Micari, Antonio; Cioppa, Angelo; Vadalà, G; Castriota, Fausto; Liso, Armando; Marchese, Alfredo; Grattoni, Chiara; Pantaleo, Paolo; Cremonesi, Alberto; Rubino, Paolo; Biamino, Giancarlo

doi:10.1016/j.jcin.2013.01.128

Cited by 79 publications

(43 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Longer term outcomes of international DCB registries have shown that the occurrence of restenosis after DCB angioplasty for de novo disease increases by 50% between 12 and 24 months. 62 A similar catch-up phenomenon has also been described after DCB angioplasty to treat ISR after SFA stenting. 63 Cautious optimism is needed to temper the enthusiasm associated with this technology.…”

Section: Drug-coated Balloonsmentioning

confidence: 64%

Endovascular Intervention for Peripheral Artery Disease

Thukkani

Kinlay

2015

Circulation Research

220

158

View full text Add to dashboard Cite

Advances in endovascular therapies during the past decade have broadened the options for treating peripheral vascular disease percutaneously. Endovascular treatment offers a lower risk alternative to open surgery in many patients with multiple comorbidities. Noninvasive physiological tests and arterial imaging precede an endovascular intervention and help localize the disease and plan the procedure. The timing and need for revascularization are broadly related to the 3 main clinical presentations of claudication, critical limb ischemia, and acute limb ischemia. Many patients with claudication can be treated by exercise and medical therapy. Endovascular procedures are considered when these fail to improve quality of life and function. In contrast, critical limb ischemia and acute limb ischemia threaten the limb and require more urgent revascularization. In general, endovascular treatments have greater long-term durability for aortoiliac disease than femoral popliteal disease. Infrapopliteal revascularization is generally reserved for critical and acute limb ischemia. Balloon angioplasty and stenting are the mainstays of endovascular therapy. New well-tested innovations include drug-eluting stents and drug-coated balloons. Adjunctive devices for crossing chronic total occlusions or debulking plaque with atherectomy are less rigorously studied and have niche roles. Patients receiving endovascular procedures need a structured surveillance plan for follow-up care. This includes intensive treatment of cardiovascular risk factors to prevent myocardial infarction and stroke, which are the main causes of death. Limb surveillance aims to identify restenosis and new disease beyond the intervened segments, both of which may jeopardize patency and lead to recurrent symptoms, functional impairment, or a threatened limb.

show abstract

Section: Drug-coated Balloonsmentioning

confidence: 64%

Endovascular Intervention for Peripheral Artery Disease

Thukkani

Kinlay

2015

Circulation Research

220

158

View full text Add to dashboard Cite

show abstract

“…of 24 months (1,2,5,8). Available angiography and duplex sonography data were used to determine the binary restenosis rate.…”

mentioning

confidence: 99%

Angioplasty of Femoral-Popliteal Arteries With Drug-Coated Balloons

Tepe

Schnorr

Albrecht

et al. 2015

JACC: Cardiovascular Interventions

239

150

View full text Add to dashboard Cite

show abstract

“…Based on a systematic literature review of clinical measures 17 , 12 publications including registries and clinical trials were used to estimate the TLR rates associated with each endovascular procedure studied [19][20][21][22][23][24][25][26][27][28][29]. More detailed information about TLR probabilities indicated in each study is shown in Table 3.…”

Section: Resultsmentioning

confidence: 99%

An analysis of the economic impact of drug-coated balloon use for the treatment of peripheral artery disease

Micari

Vadalà

Corbo

et al. 2015

ICFJ

Self Cite

View full text Add to dashboard Cite

Background: Drug-coated balloons (DCBs) are an alternative for patients with peripheral arterial disease. Costs and re-intervention rates are potentially reduced compared to other technologies. We assessed the economic impact of these endovascular therapies.Methods: An Italian National Healthcare Service-perspective budget impact model with a 5-year horizon was developed to compare relative costs of 4 index procedures (plain old balloon angioplasty (POBA), DCBs, and bare-metal and drug-eluting stents (BMSs, DESs)) based on 1-year repeat-procedure rates (target-lesion revascularization (TLR)). A published systematic review of TLR rates in patients with femoral-popliteal disease undergoing these treatments was used to measure effectiveness. Costs associated with each treatment were derived from diagnosis-related group tariffs. A decision analytic model was developed to estimate 1-year costs for index procedures and possible revascularizations. Results: Pooled TLR rates show clear patient benefits for DCBs (6.9%) compared with POBA (21.6%) and BMSs (14.2%) and non-inferiority vs. DESs (7.3%). One-year payments for index and repeat interventions (by TLR rate) showed that DCBs were the least costly strategy, saving ~€1,000/patient vs. POBA. The potential savings were €8.7M, assuming 5% annual increase in DCB adoption over 5 years. Conclusions: Despite initial higher investment, DCB represent a cost-saving alternative to other technologies.

show abstract

2-Year Results of Paclitaxel-Eluting Balloons for Femoropopliteal Artery Disease

Abstract: PEBs are associated with favorable functional and clinical outcomes at 2 years in patients with femoropopliteal artery disease requiring percutaneous revascularization.

Cited by 79 publications

References 16 publications

Endovascular Intervention for Peripheral Artery Disease

Endovascular Intervention for Peripheral Artery Disease

Angioplasty of Femoral-Popliteal Arteries With Drug-Coated Balloons

An analysis of the economic impact of drug-coated balloon use for the treatment of peripheral artery disease

Contact Info

Product

Resources

About